South Korea
· Delayed Price · Currency is KRW Genomictree Statistics
Total Valuation
Genomictree has a market cap or net worth of KRW 363.33 billion. The enterprise value is 266.29 billion.
| Market Cap | 363.33B |
| Enterprise Value | 266.29B |
Important Dates
The last earnings date was Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomictree has 23.98 million shares outstanding. The number of shares has increased by 11.58% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 23.98M |
| Shares Change (YoY) | +11.58% |
| Shares Change (QoQ) | +1.13% |
| Owned by Insiders (%) | 16.06% |
| Owned by Institutions (%) | 5.35% |
| Float | 20.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 175.40 |
| PB Ratio | 2.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -27.84 |
| EV / Sales | 130.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.88 |
Financial Position
The company has a current ratio of 20.26, with a Debt / Equity ratio of 0.02.
| Current Ratio | 20.26 |
| Quick Ratio | 19.99 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | -37.08 |
Financial Efficiency
Return on equity (ROE) is -8.00% and return on invested capital (ROIC) is -6.97%.
| Return on Equity (ROE) | -8.00% |
| Return on Assets (ROA) | -6.49% |
| Return on Capital (ROIC) | -6.97% |
| Revenue Per Employee | 25.16M |
| Profits Per Employee | -118.07M |
| Employee Count | 81 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 5.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.38% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -4.38% |
| 50-Day Moving Average | 16,345.40 |
| 200-Day Moving Average | 19,679.60 |
| Relative Strength Index (RSI) | 39.70 |
| Average Volume (20 Days) | 174,522 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomictree had revenue of KRW 2.04 billion and -9.56 billion in losses. Loss per share was -407.15.
| Revenue | 2.04B |
| Gross Profit | -1.21B |
| Operating Income | -14.39B |
| Pretax Income | -10.39B |
| Net Income | -9.56B |
| EBITDA | -13.22B |
| EBIT | -14.39B |
| Loss Per Share | -407.15 |
Balance Sheet
The company has 99.36 billion in cash and 1.95 billion in debt, giving a net cash position of 97.41 billion or 4,061.89 per share.
| Cash & Cash Equivalents | 99.36B |
| Total Debt | 1.95B |
| Net Cash | 97.41B |
| Net Cash Per Share | 4,061.89 |
| Equity (Book Value) | 129.00B |
| Book Value Per Share | 5,363.30 |
| Working Capital | 96.39B |
Cash Flow
In the last 12 months, operating cash flow was -13.32 billion and capital expenditures -2.46 billion, giving a free cash flow of -15.78 billion.
| Operating Cash Flow | -13.32B |
| Capital Expenditures | -2.46B |
| Free Cash Flow | -15.78B |
| FCF Per Share | -657.81 |
Margins
| Gross Margin | -59.27% |
| Operating Margin | -705.99% |
| Pretax Margin | -509.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -773.93% |
Dividends & Yields
Genomictree does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.58% |
| Shareholder Yield | -11.58% |
| Earnings Yield | -2.69% |
| FCF Yield | -4.34% |
Stock Splits
The last stock split was on September 14, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Sep 14, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genomictree has an Altman Z-Score of 36.65.
| Altman Z-Score | 36.65 |
| Piotroski F-Score | n/a |